Exelixis Stock News

Performance has been poor over the past five years even as executive compensation remains on the high end. Cabozantinib continues to show promising sales growth and retention of market share in key in

Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

These stand-out growth stocks are ripe for the picking following a peak decline of 34% in the Nasdaq Composite.

These two drug makers have outshined the market this year.

Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.

Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Exelixis easily beat second-quarter expectations and retained its full-year outlook on Tuesday. But EXEL stock was unmoved.

These drugmakers are flying high right now.

These transformative growth stocks are begging to be bought following a 34% peak decline in the Nasdaq.

Cabo is a blockbuster drug, but there are potential headwinds. EXEL needs to find other assets and move them to late stages.

Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.

These supercharged growth stocks can make investors rich over the long haul.

These companies' shares have outpaced the market and other biotech stocks this year.

Some say Exelixis is a one-trick pony -- but it is a pretty good trick.